CLMT Calumet, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
02:50
Sep 04
Sep 04
Watch CLMT: permit positive, MRL cash limited
Watch CLMT rather than buying; the Montana permit improves project economics and reduces funding dilution, but MRL preferred distributions and undisclosed lease terms limit near-term parent cash conversion, so this is research, not an explicit long signal.
MED
02:50
Sep 04
Sep 04
CLMT permit analysis constructive; author research only.
Watch CLMT as the analyst provides a detailed permit analysis confirming a capital-efficient MaxSAF path; the tone is constructive research, not an explicit owned position.
MED
10:20
Sep 02
Sep 02
CLMT watch on improved MaxSAF capital efficiency
Monitor CLMT as research flags the MaxSAF rescope as massively reducing capex, dilution, and financing risk; analyst PTs raised to $60-$75 with Buy ratings, but no author ownership language is present.
MED
09:02
Sep 02
Sep 02
CLMT top policy beneficiary via SREs
Watch CLMT as a strongest direct policy beneficiary via Small Refinery Exemption access improving earnings visibility.
MED
21:44
Sep 01
Sep 01
CLMT benefits from refinery exemptions, watch
Watch CLMT as a direct beneficiary of Small Refinery Exemptions providing compliance relief; no explicit author position disclosed.
MED
21:23
Sep 01
Sep 01
CLMT watch on refinery exemption benefits
Watch CLMT as a potential beneficiary of Small Refinery Exemptions; author highlights it as relatively strongest but provides no ownership stance.
MED
12:59
Sep 01
Sep 01
Calumet MaxSAF reset improves risk profile
Calumet's MaxSAF expansion revision reduces capital needs and dilution risk, improving capital efficiency, but the post is analytical research without explicit author position language. Monitor for financing and execution progress.
MED
11:36
Sep 01
Sep 01
CLMT SAF expansion watch, no position stated
Watch CLMT as the SAF expansion plan is revised with lower capital requirements, but this is a company press release posted by the author, not an explicit position statement.
MED
15:46
Aug 29
Aug 29
The author provides a detailed regulatory research note on RIN policy and SRE outcomes.
The author provides a detailed regulatory research note on RIN policy and SRE outcomes, framing market moves as context rather than expressing any personal position or forward-looking trade call.
18:45
Aug 27
Aug 27
CLMT upgraded; monitor after S&P rating boost
Monitor CLMT following the S&P upgrade to B- with stable outlook. Credit improvement is positive for the story but represents a news/rating event, not author position or conviction call.
MED
15:27
Aug 26
Aug 26
CLMT watch after positive third-party research.
Author expresses a positive but non-committal stance on CLMT after seeing another analyst's deep dive; no explicit ownership or position language is present. Watch for further signals.
MED
00:32
Aug 23
Aug 23
Watch CLMT on refining read-through
Monitor CLMT within refining-sector coverage; author highlights expert commentary but provides no explicit directional call.
MED
22:23
Aug 22
Aug 22
Watch refiners with limited Canadian crude dependence
Watch XOM, CVX, PBF, and CLMT as affected base-oil refiners with only modest direct Canadian crude dependence; this is a sourcing research map, not an author-owned long or short.
MED
13:55
Aug 21
Aug 21
Watch RIN-exposed refiners after 2026 RFS shock
Watch all six RIN-exposed refiners/biofuels names because the 2026-2027 RFS rule creates a large RIN demand shock; the post is research, not an author position.
MED
20:02
Aug 18
Aug 18
Author agrees with rotating into oil volatility names but only expresses regret about missing.
Author agrees with rotating into oil volatility names but only expresses regret about missing CLMT, not a current position or forward call.
LOW
19:19
Aug 18
Aug 18
Calumet conversion thesis is research, not owned
Watch CLMT rather than treat it as a long: the note outlines the C-Corp conversion, specialty margins, SAF optionality, and deleveraging, but includes no explicit author position.
MED
19:08
Aug 18
Aug 18
Constructive Calumet research; watch for staged entry
Watch CLMT as a research write-up: constructive and detailed, but no explicit author-owned position. Staged long only after operational/cash-flow milestones, per the author's valuation-disciplined framework.
MED
14:49
Aug 12
Aug 12
Analyze as specialty-products and renewable-fuels platform.
Watch CLMT as a specialty-products and renewable-fuels platform rather than a conventional transportation-fuel refiner.
MED
About CLMT Analyst Coverage
Buzzberg tracks CLMT (Calumet, Inc.) across 2 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 18 total trade ideas tracked. Past 7 days: 8 watch. Latest voices: TheValueist, ckcapitalxx.